23-valent PPV / Sinovac - LARVOL DELTA

Immune persistence of a single dose of 23-valent pneumococcal polysaccharide vaccine: A 6-year follow-up. (PubMed, Hum Vaccin Immunother) - P3 | "The results suggested PPV23 could provide protection 6 years after vaccination. Considering the significant decrease of antibody level, the revaccination in high-risk population may be needed.Trial registration: ClinicalTrial.gov identifier: NCT03480763."

Journal • Infectious Disease • Pneumococcal Infections

Immunogenicity and Safety of an Inactivated Quadrivalent Influenza Vaccine Administered Concomitantly with a 23-Valent Pneumococcal Polysaccharide Vaccine in Adults Aged 60 Years and Older. (PubMed, Vaccines (Basel)) - "No serious adverse events were observed. In conclusion, the immunogenicity of the concomitant administration of IIV4 and PPSV23 was non-inferior to that of the separate administration, and the safety profile was favorable in adults aged 60 years and older in China."

Journal • Infectious Disease • Influenza • Pneumococcal Infections • Respiratory Diseases

Immunogenicity and Safety of 23-valent Pneumococcal Polysaccharide Vaccine (clinicaltrials.gov) - P4 | N=1800 | Completed | Sponsor: Sinovac Biotech Co., Ltd | Recruiting ➔ Completed | Trial completion date: Nov 2024 ➔ Apr 2023 | Trial primary completion date: Nov 2024 ➔ Apr 2023

Trial completion • Trial completion date • Trial primary completion date • Infectious Disease • Pneumococcal Infections

Lot-to-lot Consistency of 23-valent Pneumococcal Polysaccharide Vaccine (clinicaltrials.gov) - P4 | N=1800 | Completed | Sponsor: Sinovac Biotech Co., Ltd | Not yet recruiting ➔ Completed | Trial completion date: Dec 2023 ➔ May 2023

Trial completion • Trial completion date • Infectious Disease • Pneumococcal Infections

Safety evaluation of simultaneous administration of quadrivalent influenza split virion vaccine and 23-valent pneumococcal polysaccharide vaccine in adults aged 60 years and older (PubMed, Zhonghua Yu Fang Yi Xue Za Zhi) - "The incidence of local adverse reactions in the two groups was 1.62% (9/554) and 0.79% (15/1 907), respectively, and the incidence of systemic adverse reactions was 1.44% (8/554) and 1.42% (27/1 907), respectively, with no statistically significant differences between them (all P>0.05). It is safe for adults aged 60 years and older to receive quadrivalent influenza split virion vaccine and 23-valent pneumococcal polysaccharide vaccine at the same time."

Journal • Infectious Disease • Influenza • Pain • Pneumococcal Infections • Respiratory Diseases

Effect of an inactivated coronavirus disease 2019 vaccine, CoronaVac, on blood coagulation and glucose: a randomized, controlled, open-label phase IV clinical trial. (PubMed, Front Immunol) - "In this randomized, controlled, open-label phase IV clinical trial, 270 participants including 135 adults aged 18-59 years and 135 adults aged 60 years or older, were enrolled and randomized to the CoronaVac group or to the control group in a 2:1 ratio and received two doses of CoronaVac or one dose of the 23-valent pneumococcal polysaccharide vaccine and one dose of inactivated hepatitis A vaccine on days 0 and 28, respectively...However, the D-dimer in the CoronaVac group decreased on day 14 compared to the value at baseline, while a higher D-dimer value, instead of a decreased D-dimer value, was a risk factor for TTS. CoronaVac showed a good safety profile and could induce a humoral response against the prototype and VOCs of SARS-CoV-2 in adults 18 years or older, with no abnormal effects on laboratory parameters of blood glucose and coagulation function."

Journal • P4 data • Cardiovascular • Hematological Disorders • Hepatology • Infectious Disease • Inflammation • Novel Coronavirus Disease • Pneumococcal Infections • Respiratory Diseases • Thrombocytopenia • Thrombosis

Lot-to-lot Consistency of 23-valent Pneumococcal Polysaccharide Vaccine (clinicaltrials.gov) - P4 | N=1800 | Not yet recruiting | Sponsor: Sinovac Biotech Co., Ltd

New P4 trial • Infectious Disease • Pneumococcal Infections

Immunogenicity and Safety of 23-valent Pneumococcal Polysaccharide Vaccine (clinicaltrials.gov) - P4 | N=1800 | Recruiting | Sponsor: Sinovac Biotech Co., Ltd | Not yet recruiting ➔ Recruiting | Trial completion date: May 2023 ➔ Nov 2024 | Trial primary completion date: Nov 2022 ➔ Nov 2024

Enrollment open • Trial completion date • Trial primary completion date • Infectious Disease • Pneumococcal Infections

A Clinical Trial of 23-valent Pneumococcal Polysaccharide Vaccine (clinicaltrials.gov) - P4 | N=600 | Completed | Sponsor: Sinovac Biotech Co., Ltd | Not yet recruiting ➔ Completed | Trial completion date: Mar 2022 ➔ Sep 2021 | Trial primary completion date: Dec 2021 ➔ Sep 2021

Trial completion • Trial completion date • Trial primary completion date • Infectious Disease • Pneumococcal Infections

Immunogenicity and Safety of 23-valent Pneumococcal Polysaccharide Vaccine (clinicaltrials.gov) - P4 | N=1800 | Not yet recruiting | Sponsor: Sinovac Biotech Co., Ltd

New P4 trial • Infectious Disease • Pneumococcal Infections

Study on Combined Vaccination With Quadrivalent Influenza Vaccine and 23-valent Pneumococcal Polysaccharide Vaccine (clinicaltrials.gov) - P4 | N=3000 | Completed | Sponsor: Sinovac Biotech Co., Ltd

New P4 trial • Infectious Disease • Pneumococcal Infections • Pneumonia • Respiratory Diseases